More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

Update on Manufacture of MPL & Tablets for Clinical Trials

Feb 1, 2022 at 10:46 PM EST · Issued by Neurizon Therapeutics Limited

Filed with ASX · Feb 1, 2022 at 10:46 PM EST · 2 pages · English

On 6ix: 6ix.com/news/update-on-manufacture-of-mpl-and-tablets-for-clinical-trials

Neurizon Therapeutics Limited on 6ix

Story so far

  • Demonstration batch of smaller size MPL tablets completedDec 1, 2021
  • MND & COVID-19 Phase 1 Clinical Trials On-TrackNov 17, 2021
  • PAA Commences Manufacture of GMP-Grade MPL for Human TrialsDec 23, 2020

Earlier from Neurizon Therapeutics

  • Epichem Awarded Contract Extension from DNDiDec 14, 2021
  • Shareholder Update - Progress and StrategyDec 12, 2021
  • Demonstration batch of smaller size MPL tablets completedNov 30, 2021
  • MND & COVID-19 Phase 1 Clinical Trials On-TrackNov 16, 2021
  • Canine phase 2b cancer trial expands to New ZealandNov 14, 2021

Later from Neurizon Therapeutics

  • Epichem Confirms Effectiveness of OHD E-Waste ProjectFeb 15, 2022
  • Appendix 4D & Half Year ReportFeb 18, 2022
  • Key Appointment to Progress MPL COVID-19 Clinical TrialFeb 20, 2022
  • Preliminary MPL antiviral leukaemia preclinical WEHI resultsFeb 23, 2022
  • MPL manufactured and tableting commencedMar 14, 2022
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer